A targeted local drug release composite particle and its preparation method and application

By targeting local drug release composite particles, using the combination of magnetic nanomaterials and biomedical degradable polymer materials, local efficient administration in stomatology is achieved, and the problems of long medication time and large amount of medication under systemic drug use are solved. It reduces the risk of adverse reactions and is suitable for the regulation of peri-radar apical and alveolar bone growth.

CN117323296BActive Publication Date: 2024-11-22SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311301455.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-09
Publication Date
2024-11-22
Estimated Expiration
2043-10-09

AI Technical Summary

Technical Problem

In the current field of oral medicine, systemic medication is often used in cases of severe trauma such as peri-root surgery, which leads to long medication time and large amounts of medication, and it is difficult to achieve local precise administration, which increases the risk of adverse reactions.

Method used

Develop a targeted local drug release composite particle, which contains the inner aqueous phase and the encapsulated oil phase, which contains the action drugs, the oil phase contains magnetic nanomaterials and biomedical degradable polymer materials, which passes the magnetic force of magnetic parts. The particles are moved in a direction and released in the target area to achieve local efficient administration.

Benefits of technology

Compared with systemic medication, this method has a reduced dosage of drugs, more accurate positioning, reduces the risk of adverse reactions, and is economical and feasible. It is suitable for applications such as peri-radar apical and alveolar bone growth regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117323296B_ABST
    Figure CN117323296B_ABST
Patent Text Reader

Abstract

The invention discloses a targeted local drug release composite particle and a preparation method and application thereof, belonging to the field of biomedical technology. The targeted local drug release composite particle comprises an inner water phase and an oil phase encapsulating the inner water phase; the components of the inner water phase include active drugs; the components of the oil phase include magnetic nanomaterials and biomedical degradable polymer materials; the mass ratio of the biomedical degradable polymer materials, the magnetic nanomaterials and the active drugs is 100-150:18-20:5-10. The targeted local drug release composite particle can achieve local drug release, and compared with systemic medication, the medication time and method are easier to control, the positioning is more accurate, the required amount of drug is less, which is conducive to reducing the risk of adverse reactions and has the advantage of economic feasibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a targeted local drug-releasing composite particle and a preparation method and application thereof. Background Art

[0002] Stomatology is an important clinical discipline, and its research content includes the most common and most frequent oral diseases with the highest incidence rate in the population, including dental hard tissue diseases, pulp diseases, periapical diseases, periodontal tissue diseases and oral mucosal diseases. If oral diseases are not treated promptly and effectively, complications may occur in the long run.

[0003] At present, in the field of oral medicine, systemic medication is usually used, especially for periapical surgery with greater trauma. This method has disadvantages such as long medication time and large amount of medication required.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] One of the purposes of the present invention is to provide a targeted local drug release composite particle, which can achieve local drug release. Compared with systemic medication, the time and method of medication are easier to control, the positioning is more accurate, and the amount of drug required is less, which is beneficial to reduce the risk of adverse reactions and has the advantage of being economically feasible.

[0006] The second object of the present invention is to provide a method for preparing the above-mentioned targeted local drug release composite particles.

[0007] The third object of the present invention is to provide an application of the above-mentioned targeted local drug release composite particles.

[0008] This application can be implemented as follows:

[0009] In a first aspect, the present application provides a targeted local drug release composite particle, which comprises an inner water phase and an oil phase encapsulating the inner water phase;

[0010] The components of the inner water phase include active drugs; the components of the oil phase include magnetic nanomaterials and biomedical degradable polymer materials;

[0011] The mass ratio of the biomedical degradable polymer material, the magnetic nanomaterial and the active drug is 100-150:18-20:5-10.

[0012] In an optional embodiment, the mass ratio of the biomedical degradable polymer material, the magnetic nanomaterial and the active drug is 100:19.5:10.

[0013] In an optional embodiment, the biomedical degradable polymer material includes at least one of poly(lactic acid-glycolic acid), poly(D,L-lactide-co-glycolide), poly(lactic acid-glycolic acid) copolymer polyethylene glycol maleimide, poly(lactic acid-glycolic acid) copolymer polyethylene glycol succinimide ester, poly(lactic acid-glycolic acid) copolymer polyethylene glycol carboxyl, poly(lactic acid-glycolic acid) copolymer polyethylene glycol amino and poly(lactic acid-glycolic acid) copolymer polyethylene glycol;

[0014] and / or, the magnetic nanomaterial comprises acid-modified ferrosoferric oxide nanoparticles;

[0015] And / or, the active drug includes at least one of parathyroid hormone, parathyroid hormone-related protein and its derivative drugs, teriparatide, abalotriptyline and its analogs.

[0016] In an optional embodiment, the targeted local drug release composite particles further include an external water phase coated on the outside of the oil phase.

[0017] In an alternative embodiment, the components of the external aqueous phase include a water-soluble film-forming agent.

[0018] In an alternative embodiment, the water-soluble film former comprises polyvinyl alcohol.

[0019] In an optional embodiment, the dosage ratio of polyvinyl alcohol to the active drug is 1:4-6.

[0020] In an optional embodiment, the average particle size of the targeted local drug release composite particles is less than 200 nm, preferably 130-170 nm.

[0021] In a second aspect, the present application provides a method for preparing composite particles for targeted local drug release according to any one of the aforementioned embodiments, comprising the following steps: encapsulating an inner aqueous phase with an oil phase.

[0022] In an optional embodiment, the active drug is added to the oil phase system according to a ratio and homogenized and emulsified for the first time, and the oil phase system includes a biomedical degradable polymer material, a magnetic nanomaterial and a first solvent.

[0023] In an alternative embodiment, the first solvent comprises dichloromethane.

[0024] In an optional embodiment, the active drug is added dropwise at a rate of 30-60 drops / min.

[0025] In an alternative embodiment, the first homogenization is performed at 14-16 krpm in an ice bath for 2-5 min.

[0026] In an optional embodiment, the method further comprises: coating the mixture after the first homogenization and emulsification with an external water phase.

[0027] In an alternative embodiment, the mixture is added to an external aqueous phase system and homogenized and emulsified for a second time.

[0028] In an optional embodiment, the mixture is added dropwise at a rate of 30-60 drops / min.

[0029] In an alternative embodiment, the second homogenization is performed at 14-16 krpm in an ice bath for 20-30 min.

[0030] In an optional embodiment, the method further comprises: removing the organic solvent in the system after the second homogenization and emulsification, washing the solid phase, and drying.

[0031] In an optional embodiment, removing the organic solvent comprises: mixing the system after the second homogenization and emulsification with an isopropanol solution or pure water, and stirring at 1400-1600 rpm for at least 6 hours.

[0032] In an alternative embodiment, the drying is performed by freeze-drying.

[0033] In an alternative embodiment, the lyophilization temperature is between -35°C and -40°C.

[0034] In a third aspect, the present application provides the use of the targeted local drug release composite particles according to any of the aforementioned embodiments, for example, the composite particles can be used as or for preparing drugs for systemic local drug release.

[0035] In an optional embodiment, the targeted local drug release composite particles are used as or for preparing drugs for local drug release in the periapical region of teeth.

[0036] In an optional embodiment, the targeted local drug release composite particles are used as or for preparing drugs for regulating alveolar bone growth.

[0037] The beneficial effects of this application include:

[0038] The targeted local drug release composite particles provided in the present application include an inner water phase and an oil phase encapsulating the inner water phase; the components of the inner water phase include active drugs; the components of the oil phase include magnetic nanomaterials and biomedical degradable polymer materials.

[0039] Based on the presence of magnetic nanomaterials in the oil phase, a magnetic part (such as a magnet) can be set up outside the body corresponding to the target drug administration area. Under the magnetic force of the magnetic part, the targeted local drug release composite particles can move to the target drug administration area in the body, and the biomedical degradable polymer material gradually degrades, so that the active drugs in the internal water phase are gradually released and act on the target drug administration area to achieve local drug release. Compared with systemic medication, this method is easier to control the time and method of medication, more accurate in positioning, and requires less drug, which is conducive to reducing the risk of adverse reactions and is more economical and feasible.

[0040] The targeted local drug-releasing composite particles can be used as or for preparing a drug for systemic local drug release, and can be particularly used as or for preparing a drug for regulating alveolar bone growth. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0042] Figure 1 This is the SEM image of the targeted local drug release composite particles in Experimental Example 1;

[0043] Figure 2 It is a statistical diagram of particle size distribution of the composite particles for targeted local drug release in Experimental Example 1;

[0044] Figure 3 TEM image of the targeted local drug release composite particles in Experimental Example 1;

[0045] Figure 4 The state diagram of the targeted local drug release composite particles in the glass sample bottle under different conditions in Experimental Example 2;

[0046] Figure 5 The figure is the experimental result of rats in the experimental group and the blank control group in Experimental Example 3;

[0047] Figures 6 to 8 This is a graph showing the effects of different experimental groups on the length of the mandibular bone, the thickness of the alveolar bone, and the height of the mandibular bone in Experimental Example 4;

[0048] Fig. 9 It is the MicroCT scan image in Experimental Example 4;

[0049] Fig.10 and Fig.11 The hemolysis result graph and hemolysis rate result graph corresponding to different experimental groups in Experimental Example 5;

[0050] Fig.12 and Fig.13 The organ slice result diagram and organ morphology result diagram corresponding to the composite particles of Test Example 6;

[0051] Fig.14 and Fig.15 These are the alkaline phosphatase activity result graph and staining result graph corresponding to different experimental groups in Experimental Example 7. DETAILED DESCRIPTION

[0052] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0053] The targeted local drug release composite particles provided in this application and their preparation method and application are described in detail below.

[0054] The present application proposes a targeted local drug release composite particle, which includes an inner water phase and an oil phase encapsulating the inner water phase. The relationship between the inner water phase and the oil phase can be understood as an oil-in-water structure.

[0055] The components of the inner water phase include active drugs; the components of the oil phase include magnetic nanomaterials and biomedical degradable polymer materials.

[0056] Based on the presence of magnetic nanomaterials in the oil phase, a magnetic part (such as a magnet) can be set up outside the body corresponding to the target drug administration area. Under the magnetic force of the magnetic part, the targeted local drug release composite particles can move to the target drug administration area in the body, and the biomedical degradable polymer material gradually degrades, so that the active drugs in the internal water phase are gradually released and act on the target drug administration area to achieve local drug release. Compared with systemic medication, this method is easier to control the time and method of medication, more accurate in positioning, and requires less drug, which is conducive to reducing the risk of adverse reactions and is more economical and feasible.

[0057] For reference, the mass ratio of biomedical degradable polymer materials, magnetic nanomaterials and active drugs can be 100-150:18-20:5-10.Such as 100:18:5, 100:18:6, 100:18:7, 100:18:8, 100:18:9, 100:18:10, 100:19:5, 100:19:6, 100:19:7, 100:19:8, 100:19:9, 100:19:10, 100:20:5, 100: 20:6, 100:20:7, 100:20:8, 100:20:9, 100:20:10, 110:18:5, 110:18:6, 110:18:7, 110:18:8, 110:18:9, 110:18:10, 110:19:5, 110:19:6, 110:19:7, 110:19:8, 110:19:9, 110:19:10, 110:20:5, 110:20:6, 110:20:7, 110:20:8, 110:20:9, 110:20:10, 120:18:5, 120:18:6, 120:18:7, 120:18:8, 120:1 8:9, 120:18:10, 120:19:5, 120:19:6, 120:19:7, 120:19:8, 120:19:9, 120:19:10, 120:20:5, 120:20:6, 120:20:7, 120:20:8, 120:20:9, 120:20:10, 130:18:5, 130:18:6, 130:18:7, 130:18:8, 130:18:9, 130:18:10, 130:19:5, 130:19:6, 130:19:7, 130:19:8, 130:19:9, 130:19:10, 130:20:5, 130:2 0:6, 130:20:7, 130:20:8, 130:20:9, 130:20:10, 140:18:5, 140:18:6, 140:18:7, 140:18:8, 140:18:9, 140:18:10, 140:19:5, 140:19:6, 140:19:7, 1 40:19:8, 140:19:9, 140:19:10, 140:20:5, 140:20:6, 140:20:7, 140:20:8, 140:20:9, 140:20:10, 150:18:5, 150:18:6, 150:18:7, 150:18:8, 150:18 :9, 150:18:10, 150:19:5, 150:19:6, 150:19:7, 150:19:8, 150:19:9, 150:19:10, 150:20:5, 150:20:6, 150:20:7, 150:20:8, 150:20:9, 150:20:10, etc.,It can also be any other ratio within the range of 100-150:18-20:5-10.

[0058] In some preferred embodiments, the mass ratio of the biomedical degradable polymer material, the magnetic nanomaterial and the active drug is 100:19.5:10. Under this ratio, the release effect of the active drug can be optimized, ensuring that the active drug can reach the target administration area before the biomedical degradable polymer material is completely degraded, and locally release the drug in the target administration area with an appropriate amount of drug.

[0059] For reference, biomedical degradable polymer materials may include, by way of example but not limitation, at least one of poly(lactic acid-glycolic acid), poly(D,L-lactide-co-glycolide), poly(lactic acid-glycolic acid) copolymer polyethylene glycol maleimide, poly(lactic acid-glycolic acid) copolymer polyethylene glycol succinimide ester, poly(lactic acid-glycolic acid) copolymer polyethylene glycol carboxyl, poly(lactic acid-glycolic acid) copolymer polyethylene glycol amino, and poly(lactic acid-glycolic acid) copolymer polyethylene glycol. In addition, other degradable polymer materials that can be used in biomedicine may also be used, which are not listed here one by one.

[0060] The magnetic nanomaterial may include, for example, acid-modified ferrosoferric oxide nanoparticles.

[0061] In some embodiments, acid-modified ferroferric oxide nanoparticles can be prepared in the following manner: Under a nitrogen atmosphere and stirring conditions, 24.00 grams of FeCl3·6H2O and 9.82 grams of FeCl2·4H2O are dissolved in 100 mL of deionized water (80°C); then 50 mL of ammonium hydroxide is quickly added, and the color of the solution immediately turns black. After 30 minutes, 3.76 grams of oleic acid are added, and the suspension is reacted at 80°C for 1.5 hours. The magnetite nanoparticles are washed with deionized water until the washed water is neutral. The oleic acid-modified magnetite nanoparticles are transferred to chloroform to obtain a stable colloidal organic iron fluid with a magnetite weight content of 65% (i.e., the acid-modified ferroferric oxide nanoparticles mentioned above).

[0062] It should be noted that, in other embodiments, it is not excluded to use other methods or conditions to prepare acid-modified ferrosoferric oxide nanoparticles.

[0063] The active drug may exemplarily but not limitatively include at least one of parathyroid hormone, parathyroid hormone-related protein and its derivative drugs, teriparatide, abalotriptide and its analogs. In addition, it may also be other drugs, which are not listed here one by one.

[0064] Furthermore, the targeted local drug release composite particles provided by the present application also include an external water phase coated on the outside of the oil phase, which can prevent the above-mentioned particulate materials with an oil-in-water structure from aggregating and adhering to each other, and can improve the compatibility of the composite particles in vivo. Accordingly, the targeted local drug release composite particles are in the form of water (external water phase) encapsulating oil, and oil encapsulating water (internal water phase).

[0065] For reference, the components of the external aqueous phase may include a water-soluble film former, such as polyvinyl alcohol.

[0066] In an optional embodiment, the dosage ratio of polyvinyl alcohol to the active drug is 1:4-6, such as 1:4, 1:4.5, 1:5, 1:5.5 or 1:6, etc.

[0067] The above-mentioned polyvinyl alcohol can be used in the form of polyvinyl alcohol aqueous solution. The concentration of polyvinyl alcohol in the polyvinyl alcohol aqueous solution can be 0.05-2wt%, such as 0.05wt%, 0.1wt%, 0.5wt%, 1wt%, 1.5wt% or 2wt%, etc., preferably 1wt%.

[0068] The average particle size of the targeted local drug release composite particles provided in the present application is less than 200 nm, preferably 130-170 nm.

[0069] It should be noted that if the average size of the targeted local drug release composite particles is greater than 200 nm, they are easily phagocytosed by macrophages and easily filtered in the liver, making it impossible to achieve local drug delivery in the target drug delivery area.

[0070] Accordingly, the present application also provides a method for preparing the above-mentioned targeted local drug release composite particles, which may include the following steps: encapsulating the oil phase with the inner water phase.

[0071] As a reference, the active drug can be added into the oil phase system according to the ratio and homogenized and emulsified for the first time.

[0072] The oil phase system comprises biomedical degradable polymer material, magnetic nano material and a first solvent. The first solvent may include (be) dichloromethane, or may be other solvents that can dissolve biomedical degradable polymer material and magnetic nano material. In a preferred embodiment, the first solvent is dichloromethane, which can effectively dissolve biomedical degradable polymer material and magnetic nano material while avoiding adverse effects on protein activity.

[0073] As an option, the active drug can be added dropwise, and the corresponding dripping speed can be 30-60 drops / min, such as 30 drops / min, 35 drops / min, 40 drops / min, 45 drops / min, 50 drops / min, 55 drops / min or 60 drops / min, etc., or it can be any other value within the range of 30-60 drops / min.

[0074] By adopting the dripping method and mixing the active drug with the oil phase system at the above-mentioned dripping speed, the oil phase system can have a better encapsulation effect on the active drug, and at the same time, the obtained granular material with an oil-in-water structure can have a smaller particle size and higher stability, which is beneficial to improving the local drug release effect of the targeted local drug release composite particles.

[0075] Optionally, the first homogenization can be carried out in an ice bath at 14-16 krpm (such as 14 krpm, 14.5 krpm, 15 krpm, 15.5 krpm or 16 krpm, etc.) for 2-5 min (such as 2 min, 3 min, 4 min or 5 min, etc.).

[0076] Furthermore, the mixture after the first homogenization and emulsification is coated with an external water phase.

[0077] Specifically, the mixture after the first homogenization and emulsification is added to the external water phase system, and then homogenized and emulsified for the second time.

[0078] Wherein, the external aqueous phase system can be a polyvinyl alcohol aqueous solution with the above concentration (0.05-2wt%).

[0079] Similarly, the mixture can be added to the external aqueous phase system by dropwise addition, and the dropwise addition speed can be 30-60 drops / min.

[0080] Alternatively, the second homogenization can be carried out in an ice bath at 14-16 krpm (such as 14 krpm, 14.5 krpm, 15 krpm, 15.5 krpm or 16 krpm, etc.) for 20-30 min (such as 20 min, 22 min, 25 min, 28 min or 30 min, etc.).

[0081] Furthermore, the organic solvent in the system after the second homogenization and emulsification is removed, the solid phase is washed, and the solid phase is dried to obtain the targeted local drug release composite particles.

[0082] Exemplarily, the removal of the organic solvent can be carried out in the following manner: the system after the second homogenization and emulsification is mixed with an isopropanol aqueous solution (the concentration can be 18-22wt%) or pure water, and stirred at 1400-1600rpm for at least 6h; in this way, all organic solvents used in the preparation process can be removed.

[0083] Washing can be done by centrifugal washing.

[0084] Alternatively, the drying may be performed by freeze drying, and the freeze drying temperature may be, for example, -35° C. to -40° C. Freeze drying is more conducive to avoiding adverse effects on the activity of the drug than drying.

[0085] In addition, the present application also provides an application of the above-mentioned targeted local drug release composite particles, for example, they can be used as or for preparing drugs for systemic local drug release.

[0086] In some optional embodiments, the above-mentioned targeted local drug release composite particles can be used as or for preparing drugs for local drug release in the periapical region of teeth.

[0087] In other optional embodiments, the above-mentioned targeted local drug release composite particles can be used as or for preparing drugs for regulating alveolar bone growth.

[0088] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0089] Example 1

[0090] This embodiment provides a targeted local drug release composite particle, which is prepared by the following preparation method:

[0091] S1: poly(lactic-glycolic acid) and acid-modified ferrosoferric oxide nanoparticles were dissolved in dichloromethane;

[0092] Among them, the mass ratio of poly (lactic acid-glycolic acid) and magnetic nanomaterial is 100:19.5.

[0093] Acid-modified ferroferric oxide nanoparticles were prepared in the following manner: 24.00 g of FeCl3·6H2O and 9.82 g of FeCl2·4H2O were dissolved in 100 mL of deionized water (80°C) under a nitrogen atmosphere and stirring; 50 mL of ammonium hydroxide was then quickly added, and the color of the solution immediately turned black. 3.76 g of oleic acid was added after 30 min, and the suspension was reacted at 80°C for 1.5 hours. The magnetite nanoparticles were washed with deionized water until the washed water was neutral. The oleic acid-modified magnetite nanoparticles were transferred to chloroform to obtain a stable colloidal organic iron fluid with a magnetite weight content of 65% (i.e., the acid-modified ferroferric oxide nanoparticles mentioned above).

[0094] S2: The abalotriptide aqueous solution was dripped into the mixture obtained in S1 at a rate of 50 drops / min, and the homogenizer was turned on at the same time. The first homogenization and emulsification was carried out in an ice bath at 15 krpm for 3 min.

[0095] Among them, the mass ratio of abalotriptyline to biomedical degradable polymer material is 10:100.

[0096] S3: The mixture obtained in S2 was dripped into a 1 wt % polyvinyl alcohol aqueous solution at a rate of 50 drops / min, and the homogenizer was turned on at the same time, and the mixture was homogenized and emulsified for a second time in an ice bath at 15 krpm for 25 min.

[0097] The mass ratio of polyvinyl alcohol to abalotriptyline in the polyvinyl alcohol aqueous solution is 5:1.

[0098] S4: The material obtained in S3 is placed in a 20 wt % isopropanol aqueous solution and magnetically stirred at a speed of 1500 rpm for 6 hours to evaporate the organic solvent.

[0099] S5: Take out the material obtained in S4 and wash it by centrifugation.

[0100] S6: Freeze-dry at -40°C to obtain composite particles for targeted local drug release.

[0101] Example 2

[0102] The difference between this embodiment and embodiment 1 is that:

[0103] In S1, the mass ratio of poly(lactic acid-glycolic acid) and magnetic nanomaterials is 125:18.

[0104] In S2, the drop rate was 30 drops / min, and the first homogenization emulsification was performed in an ice bath at 14 krpm for 5 min. The mass ratio of abalotriptyline to the biomedical degradable polymer material was 5:125.

[0105] In S3, the drop rate was 30 drops / min, and the second homogenization emulsification was performed in an ice bath at 14 krpm for 30 min. The concentration of the polyvinyl alcohol aqueous solution was 0.05 wt %, and the mass ratio of polyvinyl alcohol to abalotriptide in the polyvinyl alcohol aqueous solution was 4:1.

[0106] In S4, the material obtained in S3 is placed in an 18 wt % isopropanol aqueous solution and magnetically stirred at a speed of 1400 rpm for 8 hours to evaporate the organic solvent.

[0107] The remaining processes and conditions are the same as in Example 1.

[0108] Example 3

[0109] The difference between this embodiment and embodiment 1 is that:

[0110] In S1, the mass ratio of poly(lactic acid-glycolic acid) and magnetic nanomaterials is 150:20.

[0111] In S2, the drop rate was 60 drops / min, and the first homogenization emulsification was performed in an ice bath at 16 krpm for 2 min. The mass ratio of abalotriptyline to biomedical degradable polymer material was 7.5:150.

[0112] In S3, the drop rate was 60 drops / min, and the second homogenization emulsification was performed in an ice bath at 16 krpm for 20 min. The concentration of the polyvinyl alcohol aqueous solution was 2 wt %, and the mass ratio of polyvinyl alcohol to abalotriptide in the polyvinyl alcohol aqueous solution was 6:1.

[0113] S4: The material obtained in S3 is placed in a 22 wt % isopropanol aqueous solution and magnetically stirred at a speed of 1600 rpm for 6 hours to evaporate the organic solvent.

[0114] The remaining processes and conditions are the same as in Example 1.

[0115] Example 4

[0116] The difference between this embodiment and embodiment 1 is that the biomedical degradable polymer material is poly(lactic acid-glycolic acid).

[0117] Example 5

[0118] The difference between this embodiment and embodiment 1 is that the active drug is PTHRP.

[0119] Test Example 1

[0120] Taking the targeted local drug release composite particles prepared in Example 1 as an example, the structure and particle size thereof were tested.

[0121] The SEM image of the targeted local drug release composite particles is shown in Figure 1 As shown by Figure 1 It can be seen that the particle size of the obtained targeted local drug release composite particles is relatively uniform. The particle size of a single particle corresponding to the short horizontal line in the upper right corner of the figure is 165.56 nm, indicating that the targeted local drug release composite particles prepared in this example meet clinical requirements.

[0122] The particle size distribution statistics of the targeted local drug release composite particles are as follows Figure 2 As shown by Figure 2 It can be seen that the PDI (particle size dispersion) of the obtained targeted local drug release composite particles is low, proving that the targeted local drug release composite particles prepared in the embodiment of the present application are relatively uniform, with a peak value of 134nm, indicating that the particle size of most targeted local drug release composite particles is around 134nm.

[0123] The TEM image of the targeted local drug release composite particles is shown in Figure 3 As shown in the figure, the darker areas represent the added magnetic FeO particles. Figure 3It can be seen that the targeted local drug release composite particles prepared in the examples of the present application successfully encapsulate ferrosoferric oxide nanoparticles.

[0124] Test Example 2

[0125] Taking Example 1 as an example, 500 mg of the obtained targeted local drug release composite particles were placed in a glass sample bottle, and 5 mL of water was added to dissolve them. The dissolved state was as follows: Figure 4 The rectangular magnet was placed against the glass sample bottle, and after 57 minutes, the targeted local drug release composite particles were completely adsorbed near the magnet (as shown in the figure on the left). Figure 4 Then, the rectangular magnet was removed and the bottle was shaken, and it returned to its initial appearance (as shown in the figure corresponding to the middle 57 minutes). Figure 4 as shown in the rightmost figure).

[0126] This indicates that the magnetic properties of the targeted local drug release composite particles prepared in the present application are reproducible.

[0127] Test Example 3

[0128] The targeted local drug release composite particle solution prepared in Example 1 (500 mg of targeted local drug release composite particles dissolved in 5 mL of water) was injected into male rats weighing 200 g at the age of 6 weeks by tail vein injection as the experimental group, and a magnet was placed in the right mandibular angle area of ​​the rat. Inject once every 3 days, 0.5 mL each time. The midline of the teeth of the rats was observed after four weeks. The experiment was set up with a blank control group, that is, the composite particles without added active drugs (only oil phase + external water phase) were injected.

[0129] The results of the experimental group and the blank control group were Figure 5 As shown in (a) and (b).

[0130] Depend on Figure 5 It can be seen that: Figure 5 The rat in (a) has an enlarged right mandible and the midline of the lower teeth is deviated to the left. Figure 5 The rats in (b) were not injected with the targeted local drug release composite particles, so the midlines of the upper and lower teeth were aligned, which proved that the targeted local drug release composite particles provided in the present application can play a role in local drug release.

[0131] Test Example 4

[0132] The experimental rats (6-week-old male rats weighing 200 g) were evenly divided into 4 groups (control group, composite particle group, action drug group and targeted local drug release composite particle group), and all experimental rats were anesthetized with isoflurane (gas anesthesia).

[0133] The targeted local drug release composite particle group was injected with the targeted local drug release composite particle solution (the same as in Experimental Example 3) into the tail vein of the rat; the control group was injected with an equal amount of normal saline; the composite particle group was injected with composite particles without the addition of active drugs (only oil phase + external water phase); the active drug group was injected with a drug solution equal to the active drug in the targeted local drug release composite particle group. For all groups, a magnet with a diameter of 1 cm was tied to the right mandible of the rat, and a nickel block (non-magnetic) of the same size as the magnet was placed on the left mandible. All rats were prevented from biting off the magnet with an Elizabethan collar. The experimental period was 28 days, and all rats were free to drink water and eat during the experiment. After the experiment, the rats were killed with sodium pentobarbital, and their mandibles were collected. The mandibular length, alveolar bone thickness, and mandibular bone height were measured. The results are shown as follows. Figures 6 to 8 shown.

[0134] Depend on Figures 6 to 8 It can be seen that in the measurement items of mandibular length, alveolar bone thickness and mandibular bone height, the targeted local drug release composite particle group was significantly better than the control group, composite particle group and action drug group.

[0135] In addition, MicroCT was used to scan and analyze the mandibular bones collected from the targeted local drug release composite particle group and the control group, and three-dimensional reconstruction and landmark measurement were performed. The results are as follows Fig. 9 shown.

[0136] Depend on Fig. 9 It can be seen that the mandibular length of rats in the targeted local drug release composite particle group was significantly increased compared with that in the control group, indicating that the targeted local drug release composite particles significantly promoted the mandibular growth of rats.

[0137] Test Example 5

[0138] The hemolysis test was divided into six groups: a physiological saline group (negative control), four targeted local drug release composite particle dispersion groups (with concentrations of 12.5wt%, 25wt%, 50wt% and 100wt%, respectively, and the targeted local drug release composite particles were prepared by Example 1) and a positive control (ultrapure water group). Each group was subjected to a hemolysis test (biosafety) in accordance with the standards and methods of "Nanoparticle Hemolytic Activity Detection" in the Medical Nanomaterials Detection and Evaluation Standards. The results are shown in Table 1. Fig.10 and Fig.11 shown.

[0139] Depend on Fig.10 and Fig.11 It can be seen that the targeted local drug release composite particles of various concentrations meet the hemolysis rate requirements specified in the national standard, have good biocompatibility, and are highly safe when used in vivo.

[0140] Test Example 6

[0141] The solution of composite particles (only oil phase + external water phase) without added active drugs was injected into the mice through the tail vein. Samples were taken after 1 week, 2 weeks, 4 weeks and 8 weeks to observe the effects on organs. The results of organ section and organ morphology are shown in Figure 2. Fig.12 and Fig.13 shown.

[0142] Depend on Figure 12 to Figure 13 It can be seen that the organ sections and organ morphology show that the injection of composite particles has no obvious impact on the organs, proving that it has good safety.

[0143] Test Example 7

[0144] The experiment was divided into 4 groups (control group, composite particle group, drug group and targeted local drug release composite particle group). Each group used BCIP / NBT alkaline phosphatase colorimetric kit to promote osteogenesis and osteoblast mineralization nodule staining kit (Alizarin Red S method) to observe the osteogenic differentiation of stem cells. Fig.14 and Fig.15 shown.

[0145] Depend on Fig.14 and Fig.15 It can be seen that the targeted local drug release composite particle group has the best osteogenesis effect. In summary, the targeted local drug release composite particles provided in the present application have good biocompatibility and magnetism, can move in a directed manner under the mediation of a magnetic field, and release drugs in an ideal area, and regulate the growth of alveolar bone through the released drugs, which has strong practicality. Compared with systemic medication, this local drug release method has a smaller dosage and is less likely to produce adverse reactions. On the other hand, the time and method of medication are easier to control, and it has the advantages of accurate positioning, reduced drug dosage, and expanded medication scope. The corresponding preparation method is simple and convenient to operate.

[0146] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A targeted local drug release composite particle, characterized in that: The targeted local drug release composite particles include an inner water phase and an oil phase encapsulating the inner water phase; The components of the inner water phase include active drugs; the components of the oil phase include magnetic nanomaterials and biomedical degradable polymer materials; The mass ratio of the biomedical degradable polymer material, the magnetic nanomaterial and the active drug is 100-150:18-20:5-10; The targeted local drug release composite particles further include an external water phase coated on the outside of the oil phase; the components of the external water phase include polyvinyl alcohol; the dosage ratio of the polyvinyl alcohol to the active drug is 1:4-6; The average particle size of the targeted local drug release composite particles is less than 200 nm; The acting drugs include abalotriptyline; The magnetic nanomaterial includes acid-modified ferrosoferric oxide nanoparticles.

2. The targeted local drug release composite particle according to claim 1, characterized in that: The mass ratio of the biomedical degradable polymer material, the magnetic nanomaterial and the active drug is 100:19.5:

10.

3. The targeted local drug release composite particle according to claim 1 or 2, characterized in that: The biomedical degradable polymer material includes at least one of poly(lactic acid-glycolic acid), poly(lactic acid-glycolic acid) copolymer polyethylene glycol maleimide, poly(lactic acid-glycolic acid) copolymer polyethylene glycol succinimide ester, poly(lactic acid-glycolic acid) copolymer polyethylene glycol carboxyl, poly(lactic acid-glycolic acid) copolymer polyethylene glycol amino and poly(lactic acid-glycolic acid) copolymer polyethylene glycol.

4. The targeted local drug release composite particle according to claim 1, characterized in that: The average particle size of the targeted local drug release composite particles is 130-170 nm.

5. The method for preparing the targeted local drug release composite particles according to any one of claims 1 to 4, characterized in that: The method comprises the following steps: adding the active drug into the oil phase system according to the ratio, and performing the first homogenization and emulsification to encapsulate the oil phase with the inner water phase to obtain a mixture; The mixture is added into an external water phase system, and homogenized and emulsified for a second time, so as to coat the mixture after the first homogenization and emulsification with the external water phase; The oil phase system includes the biomedical degradable polymer material, the magnetic nanomaterial and the first solvent; the active drug is added by dripping at a rate of 30-60 drops / min; the mixture is added by dripping at a rate of 30-60 drops / min.

6. The preparation method according to claim 5, characterized in that: The first solvent includes dichloromethane.

7. The preparation method according to claim 5, characterized in that: The first homogenization was carried out at 14-16 krpm in an ice bath for 2-5 min.

8. The preparation method according to claim 5, characterized in that: The second homogenization was carried out at 14-16 krpm in an ice bath for 20-30 min.

9. The preparation method according to claim 5, characterized in that: Also includes: The organic solvent in the system after the second homogenization and emulsification is removed, and the solid phase is washed and dried.

10. The preparation method according to claim 9, characterized in that: The organic solvent removal comprises: mixing the system after the second homogenization and emulsification with an isopropanol solution or pure water, and stirring at 1400-1600 rpm for at least 6 hours.

11. The preparation method according to claim 9, characterized in that: Freeze drying was used for drying.

12. The preparation method according to claim 11, characterized in that: The freeze-drying temperature is -35°C to -40°C.

13. The use of the targeted local drug release composite particles according to any one of claims 1 to 4, characterized in that: The targeted local drug-releasing composite particles are used to prepare drugs for regulating alveolar bone growth.